Exelixis/GSK: Using Project Financing to Accelerate R&D

Productivity in biotech is a better problem to have than its opposite-but paying the higher-than-expected development costs makes it still a problem. Thanks to a variety of new project financing sources, and a particularly clever approach to amending its alliance with GlaxoSmithKline, Exelixis is fact trying to turn research productivity into a source of non-dilutive capital.

Productivity in biotech is a better problem to have than its opposite—but it's still a problem. Yet thanks to a variety of new project financing sources, and a particularly clever approach to marrying them with Big Pharma alliances, it is in fact possible to turn research productivity into a source of non-dilutive capital.

By mid- 2004, George Scangos, PhD realized his company was facing a major financing crunch. The CEO of Exelixis Inc....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes, and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.